Bausch & Lomb vs Idexx Laboratories
Bausch & Lomb is the larger business, with $5.10bn of revenue in fiscal 2025 against $4.30bn for Idexx Laboratories (1.2 times as much). Idexx Laboratories grew faster (10.4% against 6.5%). Idexx Laboratories kept more of each dollar of sales as profit: a net margin of 24.6% against -7.1%. Idexx Laboratories carries less debt relative to equity (52.8% against 79.2%).
| Latest fiscal year | Bausch & LombBLCO, 2025 | Idexx LaboratoriesIDXX, 2025 |
|---|---|---|
| Revenue | $5.10bn | $4.30bn |
| Revenue growth | 6.5% | 10.4% |
| Net income | −$360m | $1.06bn |
| Operating margin | 2.2% | 31.6% |
| Net margin | -7.1% | 24.6% |
| Return on equity | -5.6% | 66.2% |
| Free cash flow | −$66.0m | $1.06bn |
| Cash | $383m | $180m |
| Total debt | $5.11bn | $848m |
| Debt to equity | 79.2% | 52.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $1.22bn |
| Employees | — | 11,000 |
| Market value | $7.14bn | $53.19bn |
| Price vs our value range | — | Above our value range |
| Moat score | 19 (Weak) | 97 (Strong) |
| Insider trades, 12 months | 9 buys, 4 sales | 0 buys, 36 sales |